Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 2/20 | 0.63 |
| ▸ | NMT1 | P30419 | 6/20 | 0.56 |
| ▸ | NMT2 | O60551 | 5/20 | 0.56 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.47 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.47 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.46 |
| ▸ | NPY4R | P50391 | 6/20 | 0.46 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.46 |
| ▸ | NPY1R | P25929 | 4/20 | 0.46 |
| ▸ | NPY2R | P49146 | 2/20 | 0.46 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10168619 | 1.00 | TLR2 (0.63) | TLR2NMT1NMT2SIRT6SIRT1 | |
| SCHEMBL10169219 | 0.98 | TLR2 (0.63) | TLR2NMT1NMT2SIRT6SIRT1 | |
| SCHEMBL10169229 | 0.97 | TLR2 (0.61) | TLR2NMT1NMT2SIRT6SIRT1 | |
| SCHEMBL13354428 | 0.96 | TLR2 (0.57) | TLR2NMT1NMT2SIRT6SIRT1 | |
| SCHEMBL10168627 | 0.95 | TLR2 (0.55) | TLR2NMT1NMT2NPY4RNPY5R | |
| SCHEMBL10169205 | 0.94 | TLR2 (0.56) | TLR2NMT1NMT2SIRT6SIRT1 | |
| SCHEMBL10168590 | 0.94 | TLR2 (0.58) | TLR2NMT1NMT2SIRT6SIRT1 | |
| SCHEMBL10169040 | 0.93 | TLR2 (0.60) | TLR2NMT1NMT2SIRT6SIRT1 | |
| SCHEMBL10168625 | 0.93 | TLR2 (0.60) | TLR2NMT1NMT2SIRT6SIRT1 | |
| SCHEMBL10169045 | 0.93 | TLR2 (0.60) | TLR2NMT1NMT2SIRT6SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120028888-A1 | APJ RECEPTOR COMPOUNDS | ANCHOR THERAPEUTICS, INC. | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028888-A1 | APJ RECEPTOR COMPOUNDS | APLNR, AP1G1, AP2B1 | TLR2 1011/4885NMT1 2633/4885NMT2 2692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.